论文部分内容阅读
目的回顾性分析国产培美曲塞(普来乐)治疗进展性非小细胞肺癌(NSCLC)的近期疗效性和毒副反应。方法 24例经组织学及细胞学证实的晚期进展的NSCLC患者,使用国产培美曲塞单药治疗,500mg/m2,静脉滴入,d1,21d为1个周期,连用2～4个周期,进行疗效及毒副反应评价。结果 24例均可评价疗效,CR0例,PR3例,PD8例,SD13例;有效率(RR)为12.5%(3/24),疾病控制率(DCR)为45.8%(11/24)。毒副反应主要表现为轻到中度胃肠道反应和骨髓抑制。结论国产培美曲塞治疗晚期进展性NSCLC具有较好的疗效且毒副反应轻。
Objective To retrospectively analyze the short-term curative effect and side effects of domestic pemetrexed (Pulale) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Twenty-four patients with advanced stage NSCLC confirmed by histology and cytology were treated with pemetrexed alone, 500 mg/m 2 intravenous infusion, d 1 and 21 d for 1 cycle, and used for 2 to 4 cycles. Efficacy and toxicity assessment. Results Efficacy was evaluated in 24 patients, including CR0, PR3, PD8 and SD13. The effective rate (RR) was 12.5% (3/24) and the disease control rate (DCR) was 45.8% (11/24). The toxic side effects were mainly mild to moderate gastrointestinal reactions and myelosuppression. Conclusion Domestically treated pemetrexed has better curative effect and less toxic side effects in the treatment of advanced NSCLC.